Stock REGN REGENERON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Real-time Estimate Cboe BZX
Other stock markets
 02:43:58 2024-05-03 pm EDT 		5-day change 1st Jan Change
953.1 USD +1.65% Intraday chart for Regeneron Pharmaceuticals, Inc. +7.77% +8.37%
05:40pm Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $870 From $880, Hold Rating Kept MT
05:25pm Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126 MT

Evolution of the average Target Price on Regeneron Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a5917487374e084902b3ae.tb6TRczDa2xEML1Mvtc-bu4rZnP5G9qLi0z28ojMIAQ.4ce-JL2vMQMsXPI-xpxtLd9tNAapU7H--C2Cod74F3TEh6M3grI_XxcCzg~5b309ed9eb32557487abbf22809f63ac

Analyst Recommendations on Regeneron Pharmaceuticals, Inc.

Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $870 From $880, Hold Rating Kept MT
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126 MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,183 From $1,177 MT
Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,000.25 From $1,016 MT
RBC Cuts Price Target on Regeneron Pharmaceuticals to $1,185 From $1,189 MT
Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 MT
TD Cowen Adjusts Regeneron Pharmaceuticals' Price Target to $1,030 From $1,020, Keeps Buy Rating MT
UBS Adjusts Regeneron Pharmaceuticals Price Target to $1,099 From $1,090, Maintains Buy Rating MT
ANALYST RECOMMENDATIONS : Las Vegas Sands, Regeneron, Kinder Morgan, Rivian, Royal Caribbean... Our Logo
Goldman Sachs Adjusts Regeneron Pharmaceuticals Price Target to $1,126 From $1,121, Buy Rating Kept MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,177 From $1,115, Keeps Overweight Rating MT
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals MT
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals MT
Intellia Therapeutics Ends Co-Development Agreement With Regeneron DJ
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,115 From $1,104, Maintains Overweight Rating MT
RBC Raises Price Target on Regeneron Pharmaceuticals to $1,184 From $1,096, Keeps Outperform Rating MT
RBC Trims Price Target on Regeneron Pharmaceuticals to $1,096 From $1,110, Keeps Outperform Rating MT
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $925 From $850, Keeps Neutral Rating MT
UBS Adjusts Price Target on Regeneron Pharmaceuticals to $1,090 from $1,112, Maintains Buy Rating MT
Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $880 From $870, Maintains Hold Rating MT
Truist Adjusts Price Target on Regeneron Pharmaceuticals to $1,135 From $1,045, Maintains Buy Rating MT
RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,110 From $1,076 Amid 'Underappreciated' Growth Prospects for Dupixent; Outperform Kept MT
Barclays Adjusts Regeneron Pharmaceuticals' Price Target to $1,050 From $1,020, Keeps Overweight Rating MT
Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,016 From $956, Keeps Overweight Rating MT
Wells Fargo Adjusts Regeneron Pharmaceuticals' Price Target to $1,050 From $980, Keeps Overweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
937.6 USD
Average target price
1,033 USD
Spread / Average Target
+10.21%
High Price Target
1,185 USD
Spread / Highest target
+26.39%
Low Price Target
720 USD
Spread / Lowest Target
-23.21%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Regeneron Pharmaceuticals, Inc.

Deutsche Bank Securities
Goldman Sachs
Morgan Stanley
Piper Sandler
RBC Capital Markets
Oppenheimer
TD Cowen
UBS
Cantor Fitzgerald
Truist Securities
Barclays
Wells Fargo Securities
BMO Capital
Canaccord Genuity
Baird
BofA Securities
Jefferies & Co.
Raymond James
WestPark Capital
Guggenheim
JPMorgan Chase
SVB Securities LLC
EF Hutton
Cowen
Evercore ISI
Argus
Bernstein
Benchmark Capital
HC Wainwright
SVB Leerink
Credit Suisse

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. REGN Stock
  4. Consensus Regeneron Pharmaceuticals, Inc.